2023 World Conference on Lung Cancer (Posters)-P2.18. Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis

P2.18. Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis - PDF(Slides)

Back to course

Pdf Summary

The document discusses the impact of evolving treatment paradigms on survival outcomes in advanced pleural mesothelioma (PM) patients. The study is based on a retrospective analysis of patients referred to BC Cancer between January 2010 and December 2022. The main objective was to explore how patient characteristics, tumor characteristics, and treatment history influence real-world survival outcomes in the context of changing treatment options.<br /><br />The results show that only 38% of patients received any systemic therapy, with 11% receiving second-line systemic therapy. Patients with sarcomatoid histology and poor performance status were less likely to receive systemic therapy. The use of dual anti-PD-1 anti-CTLA-4 immunotherapy as first-line treatment for PM showed promising results, with encouraging overall survival (OS) benefits regardless of performance status and histology.<br /><br />Preliminary analysis suggests that immunotherapy may provide a similar OS advantage to platinum-doublet chemotherapy as reported in the CheckMate-743 trial. Cox-regression analysis indicates that first-line platinum-doublet chemotherapy or immunotherapy remains independently associated with better OS outcomes.<br /><br />However, despite the availability of immunotherapy, patients with ECOG 2 and non-epithelioid histology still have a poor prognosis. The document also includes figures illustrating the distribution of histology and performance status among patients, as well as a swimmer's plot of treatment history.<br /><br />In conclusion, the study shows promising results for immunotherapy as a first-line treatment for advanced pleural mesothelioma. Further follow-up is needed to assess the long-term impact of immunotherapy on patient outcomes. The research is supported by the Eleni Skalbania Endowment for Lung Cancer Research and BC Cancer Foundation.

Asset Subtitle

Florence Wu

Meta Tag

Speaker Florence Wu

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

evolving treatment paradigms

survival outcomes

advanced pleural mesothelioma

retrospective analysis

systemic therapy

anti-PD-1

anti-CTLA-4 immunotherapy

overall survival

platinum-doublet chemotherapy

immunotherapy